拉貝珠單抗
化合物
拉貝珠單抗（INN：labetuzumab；商品名CEA-CIDE）是一種人源化IgG1單株抗體，用於治療結直腸癌。[1]它選擇性地結合CEACAM5。[2]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 癌胚抗原 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 219649-07-7  |
| ChemSpider |
|
| UNII | |
| KEGG | |
該藥物還被用在患有轉移的甲狀腺髓樣癌患者中進行了測試。[3]
該藥物由Immunomedics開發。
參考資料
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab (PDF). WHO Drug Information. 2002, 16 (1): 95 [2024-03-13]. （原始內容存檔 (PDF)於2024-07-31）.
- ^ labetuzumab-SN-38 immunoconjugate IMMU-130. National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. [2024-03-13]. （原始內容存檔於2015-05-11）.
- ^ Stein, Rhona; Goldenberg, David M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics. 2004-12, 3 (12) [2024-03-13]. ISSN 1535-7163. PMID 15634649. （原始內容存檔於2024-03-13）.